[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celularity Inc (CELU)

Celularity Inc (CELU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 27,598
  • Shares Outstanding, K 28,838
  • Annual Sales, $ 54,220 K
  • Annual Income, $ -57,890 K
  • EBIT $ -47 M
  • EBITDA $ -39 M
  • 60-Month Beta 0.45
  • Price/Sales 0.92
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.33
  • Most Recent Earnings $-0.88 on 11/14/25
  • Next Earnings Date 09/04/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 286.35% (-43.07%)
  • Historical Volatility 61.61%
  • IV Percentile 77%
  • IV Rank 24.11%
  • IV High 900.41% on 12/23/25
  • IV Low 91.28% on 09/08/25
  • Expected Move (DTE 12) 0.0850 (8.88%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 256
  • Volume Avg (30-Day) 47
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 756
  • Open Int (30-Day) 620
  • Expected Range 0.8720 to 1.0420

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-2.20
  • Growth Rate Est. (year over year) +45,509.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9305 +2.85%
on 04/30/26
1.4500 -34.00%
on 04/08/26
-0.3530 (-26.95%)
since 04/01/26
3-Month
0.9305 +2.85%
on 04/30/26
1.5100 -36.62%
on 02/18/26
-0.2630 (-21.56%)
since 01/30/26
52-Week
0.9305 +2.85%
on 04/30/26
4.3500 -78.00%
on 07/22/25
-0.6139 (-39.08%)
since 05/01/25

Most Recent Stories

More News
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused regenerative and cellular medicine company, today announced...

CELU : 0.9570 (+2.43%)
CELUW : 0.0090 (unch)
NEXGEL Appoints Ian Blackman as Chief Financial Officer

Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL”...

CELU : 0.9570 (+2.43%)
NXGL : 0.5811 (-1.54%)
NXGLW : 0.0599 (-9.24%)
NEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease Segment

Transaction expected to approximately triple NEXGEL’s annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified...

CELU : 0.9570 (+2.43%)
NXGL : 0.5811 (-1.54%)
NXGLW : 0.0599 (-9.24%)
Celularity Announces Closing of Transaction with NexGel

FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced the closing of...

CELU : 0.9570 (+2.43%)
CELUW : 0.0090 (unch)
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

FLORHAM PARK, N.J., April 17, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that on April...

CELU : 0.9570 (+2.43%)
CELUW : 0.0090 (unch)
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  ...

CELU : 0.9570 (+2.43%)
NXGL : 0.5811 (-1.54%)
NXGLW : 0.0599 (-9.24%)
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications. Three pipeline...

CELU : 0.9570 (+2.43%)
NXGL : 0.5811 (-1.54%)
CELUW : 0.0090 (unch)
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

Transaction expected to approximately triple NEXGEL’s annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified...

CELU : 0.9570 (+2.43%)
NXGL : 0.5811 (-1.54%)
NXGLW : 0.0599 (-9.24%)
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy

Transaction expected to generate up to $35 million in upfront and milestone payments Celularity retains exclusive manufacturing rights, creating continued biomaterials revenue and margin opportunity ...

CELU : 0.9570 (+2.43%)
CELUW : 0.0090 (unch)
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2...

CELU : 0.9570 (+2.43%)
CELUW : 0.0090 (unch)

Business Summary

Celularity Inc. is a clinical stage biotechnology company. It involved in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified NK cells, genetically-modified NK cells, T cells engineered with a CAR and mesenchymal-like adherent stromal cells...

See More

Key Turning Points

3rd Resistance Point 1.2923
2nd Resistance Point 1.2207
1st Resistance Point 1.0888
Last Price 0.9570
1st Support Level 0.8853
2nd Support Level 0.8137
3rd Support Level 0.6818

See More

52-Week High 4.3500
Fibonacci 61.8% 3.0438
Fibonacci 50% 2.6402
Fibonacci 38.2% 2.2367
Last Price 0.9570
52-Week Low 0.9305

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.